Assertio Therapeutics Inc (ASRT) stock news · rev $118.7M
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
This ASRT news page leads with what Assertio Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for ASRT yet. We will not pad this page with generic market recap.
Latest reported ASRT revenue for 2025-12-31 was $118.7M. Net income was -$30.4M. Revenue was down 5.0% from 2024-12-31 to 2025-12-31. ASRT currently screens at market cap $151.5M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ASRT stock page; for the tape open the quote page.
ASRT stock news FAQ
What are ASRT's latest revenue and net income?
Latest cached Assertio Therapeutics Inc (ASRT) revenue for Dec 31, 2025 was $118.7M. Net income was -$30.4M. Statements: https://lician.com/financials/asrt
How did ASRT revenue change from the prior cached period?
Cached Assertio Therapeutics Inc (ASRT) revenue was down 5.0% from $125.0M (Dec 31, 2024) to $118.7M (Dec 31, 2025). Statements: https://lician.com/financials/asrt
What is ASRT's market cap?
Assertio Therapeutics Inc (ASRT) market cap is $151.5M on the latest cached fundamentals snapshot.
What kind of company is ASRT?
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
Where is ASRT stock news listed?
Cached stock news for Assertio Therapeutics Inc (ASRT) is listed at https://lician.com/news/asrt. Filings: https://lician.com/sec/asrt
Not investment advice.